Compass Pathway News Today

By Sriparna Roy and Pratik Jain (Reuters) - A panel of advisers to the U.S. Food and Drug Administration will meet on Tuesday to discuss a therapy based on the psychedelic drug MDMA for patients with post-traumatic stress disorder (PTSD). The meet...

New research led by the University of Bristol has explored the neuropsychological effects of rapid-acting antidepressants, including ketamine, scopolamine and p

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

By Sabela Ojea International stocks trading in New York closed lower on Tuesday. The S&P/BNY Mellon index of American depositary receipts fell 1.5% to 148.45. The European index dived 1.6% to 145.63, the Asian index declined 1.3% to 168.53... | May. 30

Compass Pathways is running a massive clinical trial that will likely help it turn a psychedelic substance into an approved medicine.

A single dose of 25 milligrams reduced symptoms of depression in people for whom several conventional treatments had failed, study.

For years, scientists have been looking ever more seriously at the therapeutic effect of psychedelics, which are not legal under U.S. federal law. However, despite this renewed interest, large-scale studies are still lacking. Last week, researchers took an important step to fill this ...

Daily Express is the sister paper of Overseas Chinese Daily News (OCDN). It was founded by the late Tan Sri Yeh Pao Tzu and the first issue hit the streets on March 1, 1963. Published in trilingual ie English, Bahasa Malaysia and Kadazan, it is by far the largest circulation daily newspaper in Sabah.

Clinical trial demonstrates positive results for therapeutic use of psilocybin.

For years, scientists have been looking ever more seriously at the therapeutic effect of psychedelics, which are not legal under US federal law. However,